PEOPLE - UK private equity and venture capital firm 3I makes appointment:
This article was originally published in Clinica
As part of its aim to increase its investment in healthcare, London-based UK private equity and venture capital firm 3i has appointed Peter Chambre as an industrialist-in-residence. Mr Chambre has 13 years' experience of leading healthcare companies, including Bespak (CEO), the Cambridge Antibody Technology Group (CEO) and Celera Genomics Group (COO). As part of 3i's industrialist-in-residence programme, Mr Chambre will identify, evaluate and complete deals in the healthcare sector, and provide significant levels of leadership assistance to businesses that are backed by 3i. Mr Chambre is currently a non-executive director of BTG (life sciences, UK) and Spectris (precision engineering, UK).
You may also be interested in...
India has proposed three categories for grouping genetically edited organisms based on the complexity of modifications.
Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.